Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0. Over 3 fiscal years it compounded at +8.0% a year.

Context

  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$1.23M+11.8% YoY
LTMMar 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+11.8%——
3-year CAGR+8.0%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.23M USD
Year-over-year change
+11.8%
4-year CAGR
+12.3%

Cost of Revenue vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's LTM Mar 2026 cost of revenue of $0 is the 2nd highest of the 3 companies compared; the peer median is $1.32M.
DRTS Competitors Peer median
Cost of Revenue for DRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$2.63M ——426.2%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 —+8.0%—
AKTSAktis Oncology, Inc.FY2025$0 ——0.0%
Peer median (excluding DRTS) $1.32M——213.1%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue776K979K1.07M1.1M1.23M
Gross Profit(776K)(979K)(1.07M)(1.1M)(1.23M)
Gross Margin—————
Research & Development11.45M20.89M26.42M27.02M30.83M
Selling, General & Admin2.34M11.25M9.26M7.92M10.22M
Operating Expenses13.79M32.14M34.61M34.94M41.06M
Depreciation & Amortization776K979K1.07M1.1M1.23M
EBITDA(13.22M)(32.74M)(28.03M)(30.3M)(41.06M)
EBITDA Margin—————
Operating Income(13.79M)(32.14M)35.68M(36.04M)(42.29M)
Operating Margin—————
Interest Income211K1.79M4.76M4.28M3.84M
Interest Expense13.27M1.77M39K344K419K
Other Income / Expenses(13.47M)(1.61M)6.54M4.3M(218K)
Income Before Tax(27.26M)(33.74M)(29.14M)(31.74M)(42.51M)
Pre-Tax Margin—————
Income Tax Expense7K20K16K6K121K
Net Income(27.27M)(33.76M)(29.16M)(31.75M)(42.63M)
Net Margin—————
EPS (Basic)(0.67)(0.53)(0.42)(0.45)(0.53)
EPS (Diluted)(0.67)(0.53)(0.42)(0.45)(0.53)
Weighted Avg Shares40.53M63.53M69.38M69.93M80.58M
Weighted Avg Shares (Diluted)40.53M63.53M69.38M69.93M80.58M

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.